When absence of evidence equates to evidence of absence: the case of routine use of cerebral embolic protection devices in transcatheter aortic valve implantation

Objectives This updated hierarchical Bayesian meta-analysis aims to integrate the latest randomised controlled trials (RCTs) on the use of cerebral embolic protection (CEP) in transcatheter aortic valve implantation (TAVI) into previously available data, providing a definite answer to the clinical effectiveness of CEP in TAVI patients. Methods A systematic search was updated on 31 March 2025. RCTs were included when comparing transfemoral TAVI with use of CEP versus transfemoral TAVI without CEP. The primary outcome was all stroke, while the secondary outcome was disabling stroke. A hierarchical Bayesian meta-analysis was performed on the (log) relative risk (RR) scale and transformed to absolute risk differences (ARDs) and numbers needed to treat (NNTs). The threshold for clinical relevance was based on published expert consensus and established on 1.1% ARD (NNT 91). Results The study was updated with one new RCT, totalling a number of eight RCTs (n=11 590, CEP n=5921 patients, control n=5669 patients). The prevalence of all stroke and disabling stroke was 2.9% and 1.4% in the control group. The median RR for all stroke was 0.94 (95% credible interval (CrI) 0.72–1.25), translating to a mean of −0.17% ARD (NNT 588), and a posterior probability of a clinically relevant CEP effect of <1%. The median RR for disabling stroke was 0.76 (95% CrI 0.44–1.23), translating to a mean of −0.36% ARD (NNT 278), and a posterior probability of a clinically relevant CEP effect of <1%. Conclusion Current-generation CEP devices are ineffective in reducing periprocedural TAVI-stroke risk to a clinically relevant degree, rendering future trials with these devices futile. PROSPERO registration number CRD42023407006.

• Publication year

  2025

• Venue

  Heart

• Publication date

  2025-06-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/heartjnl-2025-326208PMID 40500116
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Routine Cerebral Embolic Protection during Transcatheter Aortic-Valve Implantation.

  2025cited by this paper
• Bayesian Analytical Methods in Cardiovascular Clinical Trials: Why, When, and How.

  2024influential reference
• Impact of Cerebral Embolic Protection Devices on Disabling Stroke After TAVR: Updated Results From the STS/ACC TVT Registry

  2024cited by this paper
• Cerebral embolic protection during transcatheter heart interventions.

  2023cited by this paper
• Stroke reduction by cerebral embolic protection devices in transcatheter aortic valve implantation: a systematic review and Bayesian meta-analysis

  2023cited by this paper
• Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement.

  2022cited by this paper
• Randomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Replacement: REFLECT II.

  2021cited by this paper
• A randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial.

  2021cited by this paper
• Interpreting results and drawing conclusions

  2019cited by this paper
• Minimal Clinically Important Difference for Safe and Simple Novel Acute Ischemic Stroke Therapies

  2017influential reference
• Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement.

  2017cited by this paper
• Effect of a Cerebral Protection Device on Brain Lesions Following Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis: The CLEAN-TAVI Randomized Clinical Trial.

  2016cited by this paper
• Filter-based cerebral embolic protection with transcatheter aortic valve implantation: the randomised MISTRAL-C trial.

  2016cited by this paper
• Transcatheter Aortic-Valve Replacement.

  2016cited by this paper
• A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial.

  2015cited by this paper
• Risk of stroke after transcatheter aortic valve implantation (TAVI): a meta-analysis of 10,037 published patients.

  2012cited by this paper

• Are We Missing the Forest for the Trees? How Bayesian Meta‐Analysis Could Reshape Evidence in Cardiology

  2025cites this paper